LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.38 -0.83

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.35

Max

2.43

Belangrijke statistieken
By Trading Economics
Inkomsten	-27M -17M
Verkoop	586K 718K
EPS	-0.125
Winstmarge	-2,366.017
Werknemers	23
EBITDA	-5.5M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+122.08% upside

Dividenden
By Dow Jones
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-25M 458M
Vorige openingsprijs	3.21
Vorige sluitingsprijs	2.38

Nieuwssentiment

By Acuity

50%

159 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.275 / 0.33 Steun & Weerstand

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mei 2026, 22:52 UTC

Belangrijke Marktbewegers

Osisko Shares Fall on Planned Convertible Notes Offering

20 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mei 2026, 23:44 UTC

Winsten

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mei 2026, 23:35 UTC

Marktinformatie

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mei 2026, 23:30 UTC

Marktinformatie

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mei 2026, 23:15 UTC

Marktinformatie

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mei 2026, 23:14 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mei 2026, 23:02 UTC

Marktinformatie

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 22:27 UTC

Marktinformatie

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mei 2026, 22:14 UTC

Marktinformatie

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mei 2026, 22:10 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mei 2026, 22:00 UTC

Winsten

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mei 2026, 21:38 UTC

Winsten

Acquisities, Fusies, Overnames

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mei 2026, 21:27 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mei 2026, 21:20 UTC

Winsten

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mei 2026, 21:19 UTC

Winsten

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mei 2026, 21:18 UTC

Winsten

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mei 2026, 21:17 UTC

Winsten

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mei 2026, 21:16 UTC

Winsten

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

122.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.33 USD 122.08%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

159 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.